EHA Library - The official digital education library of European Hematology Association (EHA)

INFLUENCE OF INFLAMMATORY CYTOKINES ON GENESIS OF ANEMIA IN LYMPHOPROLIFERATIVE DISORDER’S PATIENTS
Author(s): ,
Tatyana Glazanova
Affiliations:
clinical immunology,Russian research institute of hematology and transfusiology,Saint-Petersburg,Russian Federation
,
Olga Rozanova
Affiliations:
clinical immunology,Russian research institute of hematology and transfusiology,Saint-Petersburg,Russian Federation
Nikolay Romanenko
Affiliations:
clinical hematology,Russian research institute of hematology and transfusiology,Saint-Petersburg,Russian Federation
(Abstract release date: 05/17/18) EHA Library. Romanenko N. 06/14/18; 216752; PB1978
Mr. Nikolay Romanenko
Mr. Nikolay Romanenko
Contributions
Abstract

Abstract: PB1978

Type: Publication Only

Background
The inflammatory cytokines (IC) play an important role in immune response to inflammation and tumor growth. Increase of their systemic level suggests the active status of immune system. However, these cytokines not only inhibit tumor growth, but can also exert myelosuppressive effect on hemopoiesis leading to development of cytopenia, including anemia.

Aims
To evaluate the influence of some IC on the development of anemia in patients with lymphoproliferative disorders (LPD).

Methods
We have examined the following groups: 1) patients with anemia (Hb 89,5±15,9 g/L; n=39) age 22-82 years, of them with II and III st. multiple myeloma – 20 patients, III-IV st. Non-Hodgkin's lymphoma – 8, st. С chronic lymphocytic leukaemia – 11; 2) healthy volunteers (Hb ≥120 g/L; n=15) age 19-76 years, as a control group. We have evaluated serum levels of the following IC: tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and interferon-γ (INF-γ).

Results
We have revealed that the level of studied IC in the group of patients was several times higher than in the control group: 1) TNF-α level in patients with anemia was 130,8±36,2 pg/ml (n=39) vs. 42,1±13,2 pg/ml in control group (n=15), p<0,01; 2) IL-1β 484,1±66,5 pg/ml (n=30) vs. 177,0±43,7 pg/ml (n=15), respectively, p<0,01; 3) IL-6 – 466,2±42,9 pg/ml (n=19) vs. 128,0±36,5 pg/ml (n=15), respectively, p<0,01; 4) INF-γ – 604,5±57,4 pg/ml (n=30) vs. 47,7±6,6 pg/ml (n=15), respectively, p<0,0001. Correlation analysis have revealed significant associations between serum levels of TNF-α and INF-γ (r=+0,41; p<0,05; n=25), TNF-α and IL-1β (r=+0,62; p<0,01; n=18), and INF-γ and IL-1β (r=+0,49; p<0,01; n=30), suggesting their synergistic action. At the same time, there were no correlations between serum IL-6 and other listed above cytokines (p>0,05). Also there was significant negative association between Hb (reflecting the severity grade of anemia) and such cytokines as IL-1β (r=-0,46; p<0,01; n=30) and TNF-α (r=-0,58; p<0,01; n=21), indicating their negative influence on erythropoiesis, and genesis of anemia. In control group there have not been revealed any associations – either between different IC and Hb (p>0,05).

Conclusion
This study have revealed the synergistic action of TNF-α, IL-1β and INF-γ, suggesting their role in genesis of anemia of LPD.

Session topic: 29. Enzymopathies, membranopathies and other anemias

Keyword(s): Anemia, Cytokine, Lymphoproliferative disorder, Multiple Myeloma

Abstract: PB1978

Type: Publication Only

Background
The inflammatory cytokines (IC) play an important role in immune response to inflammation and tumor growth. Increase of their systemic level suggests the active status of immune system. However, these cytokines not only inhibit tumor growth, but can also exert myelosuppressive effect on hemopoiesis leading to development of cytopenia, including anemia.

Aims
To evaluate the influence of some IC on the development of anemia in patients with lymphoproliferative disorders (LPD).

Methods
We have examined the following groups: 1) patients with anemia (Hb 89,5±15,9 g/L; n=39) age 22-82 years, of them with II and III st. multiple myeloma – 20 patients, III-IV st. Non-Hodgkin's lymphoma – 8, st. С chronic lymphocytic leukaemia – 11; 2) healthy volunteers (Hb ≥120 g/L; n=15) age 19-76 years, as a control group. We have evaluated serum levels of the following IC: tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and interferon-γ (INF-γ).

Results
We have revealed that the level of studied IC in the group of patients was several times higher than in the control group: 1) TNF-α level in patients with anemia was 130,8±36,2 pg/ml (n=39) vs. 42,1±13,2 pg/ml in control group (n=15), p<0,01; 2) IL-1β 484,1±66,5 pg/ml (n=30) vs. 177,0±43,7 pg/ml (n=15), respectively, p<0,01; 3) IL-6 – 466,2±42,9 pg/ml (n=19) vs. 128,0±36,5 pg/ml (n=15), respectively, p<0,01; 4) INF-γ – 604,5±57,4 pg/ml (n=30) vs. 47,7±6,6 pg/ml (n=15), respectively, p<0,0001. Correlation analysis have revealed significant associations between serum levels of TNF-α and INF-γ (r=+0,41; p<0,05; n=25), TNF-α and IL-1β (r=+0,62; p<0,01; n=18), and INF-γ and IL-1β (r=+0,49; p<0,01; n=30), suggesting their synergistic action. At the same time, there were no correlations between serum IL-6 and other listed above cytokines (p>0,05). Also there was significant negative association between Hb (reflecting the severity grade of anemia) and such cytokines as IL-1β (r=-0,46; p<0,01; n=30) and TNF-α (r=-0,58; p<0,01; n=21), indicating their negative influence on erythropoiesis, and genesis of anemia. In control group there have not been revealed any associations – either between different IC and Hb (p>0,05).

Conclusion
This study have revealed the synergistic action of TNF-α, IL-1β and INF-γ, suggesting their role in genesis of anemia of LPD.

Session topic: 29. Enzymopathies, membranopathies and other anemias

Keyword(s): Anemia, Cytokine, Lymphoproliferative disorder, Multiple Myeloma

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies